Latest market price
85.88
-1.53-1.75%
CDNAQT77CareDx, Inc·NASDAQ
85.88-1.75%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index—P/E35.93EPS (ttm)2.39Insider Own8.90%Shs Outstand51.73MPerf Week24.28%
Market Cap4.44BForward P/E54.40EPS next Y1.58Insider Trans-7.38%Shs Float49.46MPerf Month27.89%
Enterprise Value4.21BPEG2.88EPS next Q0.24Short Float13.58%Perf Quarter82.37%
Income129.00MP/S8.94EPS this Y—Short Ratio5.30Perf Half Y309.73%
Sales497.00MP/B9.51EPS next Y-11.37%ROA20.05%Short Interest6.72MPerf YTD355.84%
Book/sh9.03P/C17.77EPS next 5Y12.47%ROE34.08%52W High90.87 -5.49%Perf Year493.50%
Cash/sh4.83P/FCF72.83EPS past 3/5Y—ROIC0.81%52W Low14.27 501.82%Perf 3Y1603.97%
Dividend Est.—EV/EBITDA150.46Sales past 3/5Y5.68% 14.63%Gross Margin70.97%Volatility7.55% 6.72%Perf 5Y21.88%
Dividend TTM—EV/Sales8.48EPS Y/Y TTM100.64%Oper. Margin0.83%ATR (14)4.99Perf 10Y2096.42%
Dividend Ex-Date—Quick Ratio2.25Sales Y/Y TTM38.44%Profit Margin25.86%RSI (14)78.19Recom2.21
Dividend Gr. 3/5Y—Current Ratio2.31EPS Q/Q—SMA2024.59%Beta2.48Target Price75.25
Payout0.00%Debt/Eq0.04Sales Q/Q39.00%SMA5041.54%Rel Volume1.70Prev Close87.41
Employees763LT Debt/Eq0.04EarningsFeb 23SMA200152.83%Avg Volume1.29MPrice85.88
IPO DateJul 17, 2014Option/ShortYes / YesEPS/Sales Surpr.174.68% 14.27%Net Debt/EBITDA-8.21Volume2,190,525Change-1.75%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-30-26ReiteratedCanaccord GenuityBuy$65 → $99
Oct-30-26ReiteratedBTIGBuy$81 → $92
Oct-27-26ReiteratedBTIGBuy$74 → $81
Sep-24-26ReiteratedBTIGBuy$60 → $74
Sep-02-26InitiatedCanaccordBuy$65
Aug-06-26ReiteratedBTIGBuy$45 → $60
Aug-03-26ReiteratedCraig-HallumBuy$35 → $64
Jul-31-26ReiteratedHC Wainwright & Co.Neutral$25 → $46
Jul-16-26ReiteratedCraig-HallumBuy$26 → $35
Jul-16-26ReiteratedBTIGBuy$28 → $45
Latest News· Times ET
Oct-30-26
Oct-30-2606:04PM
Oct-29-26
Oct-27-26
Oct-26-26
Oct-22-26
Oct-19-26
Oct-16-26
Oct-15-26
Oct-12-26
Oct-07-26
Oct-05-26
Sep-30-26
Company

CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue497380334280—————
Cost of Goods Sold Incl. D&A145123110102—————
Gross Profit353257224178—————
Selling, General and Administrative Excl. Other265210206201—————
Research and Development83717282—————
Other Operating Expense11-9599—————
Operating Income4-2541-203—————
Interest Expense
0000—————
Unusual Expense
—————————
Non-Operating Income (Expense)12041213—————
Net Income Before Taxes125-2153-190—————
Income Taxes
-5000—————
Consolidated Net Income129-2153-190—————
Net Income From Continuing Operations129-2153-190—————
Net Income129-2153-190—————
EPS (Recurring)2.49-0.401.00-3.54—————
EPS (Basic, Before Extraordinaries)2.49-0.401.00-3.54—————
EPS (Diluted)2.39-0.400.93-3.54—————
EBITDA28-5-34-85—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio35.93—23.02——————
Price To Sales Ratio8.992.633.402.31—————
Gross Margin71.0367.6367.0763.57—————
Operating Margin0.80-6.5812.28-72.50—————
Net Margin25.96-5.5315.87-67.86—————
Shares Outstanding52535354—————
Market Capitalization4,4669991,135648—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$98.61$74.34$50.07$25.80$1.53● Close Price0.00M1.37M2.75M4.12M5.50MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Bickerstaff GeorgeDirectorAug 05 '26Sale46.2820,000925,700134,061Aug 06
Novack Jeffrey AdamSecretary and General CounselAug 05 '26Sale46.262,688124,349106,075Aug 06
COURNOYER CHRISTINEDirectorAug 04 '26Sale46.9416,000750,97342,943Aug 06
Goldberg MichaelDirectorAug 04 '26Sale47.0644,7002,103,49761,738Aug 06
Hanna John Walter JRPresident and CEOJul 16 '26Sale37.79118,0004,458,637653,448Jul 17
Hanna John Walter JRPresident and CEOJul 16 '26Option Exercise8.20118,000967,600771,448Jul 17
Valantine HannahDirectorJul 16 '26Option Exercise14.7628,779424,89565,465Jul 17
Valantine HannahDirectorJul 16 '26Sale36.1528,7791,040,24336,686Jul 17
Hanna John Walter JRPresident and CEOJun 29 '26Option Exercise8.2039,900327,180701,859Jun 30
Hanna John Walter JRPresident and CEOJun 29 '26Sale29.2439,9001,166,836661,959Jun 30
Hanna John Walter JRPresident and CEOJun 26 '26Option Exercise8.20100820662,059Jun 30
Hanna John Walter JRPresident and CEOJun 26 '26Sale29.001002,900661,959Jun 30
Hanna John Walter JRPresident and CEOJun 15 '26Option Exercise8.2015,676128,543661,959Jun 30
Hanna John Walter JRPresident and CEOJun 11 '26Option Exercise8.2013,618111,668646,283Jun 30
Hanna John Walter JRPresident and CEOJun 04 '26Option Exercise8.207065,789632,665Jun 30
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.